Crestor (Rosuvastatin) Cost in Connecticut: Prices, Insurance, and Savings in 2026

Rosuvastatin is a statin (HMG-CoA reductase inhibitor) available as the brand-name product Crestor and as generic rosuvastatin calcium tablets in 5 mg, 10 mg, 20 mg, and 40 mg strengths. It is FDA-approved for lowering LDL cholesterol, reducing cardiovascular risk in certain patients, and slowing progression of atherosclerosis. Generic versions have been available in the United States since patent exclusivity ended in 2016.

The central cost question for Connecticut patients is not "what does Crestor cost" but "why would anyone pay the brand price when a generic exists." Generic rosuvastatin is almost always the lower-cost, clinically equivalent option, and the article below separates what is stable and well-established (FDA approval status, drug class, generic availability, guideline positioning) from what changes often and needs a same-day check (insurer tier placement, Medicaid prior-authorization outcomes, specific cash prices at a given pharmacy).

What this page can say with confidence: generic rosuvastatin is a low-cost, widely available statin because it has lost patent protection and multiple manufacturers produce it, while brand Crestor remains substantially more expensive because it is sold under a single manufacturer's list price. Connecticut Medicaid (HUSKY Health) and most commercial plans in the state cover rosuvastatin, but the exact copay, tier, and prior-authorization outcome depend on the specific plan and change over time. Nothing in the publicly available literature we reviewed supports a precise, current dollar figure for either brand or generic rosuvastatin at Connecticut pharmacies, so any specific price you see quoted, including elsewhere on the internet, should be confirmed directly with the pharmacy or insurer before you rely on it.

Brand vs. generic: the actual decision

Because rosuvastatin calcium is generic, the clinical ingredient in a generic tablet is the same as in brand Crestor. The FDA's Orange Book lists multiple approved generic manufacturers, which is what drives retail price competition once a drug loses exclusivity. In practice, this means:

• Generic rosuvastatin is typically the default choice unless a patient has a documented reason to need the brand product specifically (which is uncommon, since bioequivalence is the basis for generic approval).
• Brand-name Crestor's manufacturer list price is set by AstraZeneca and is not something this article can state as a fixed current figure, since list prices change and the source material available to us does not include a dated, verifiable 2026 figure.
• Actual pharmacy cash prices (what an uninsured patient pays at the counter) vary by chain, location, and day, and are not something a general article can quote as a single Connecticut-wide number without pulling from a live pricing tool at the time of fill.

If you want a real number, the reliable approach is to call two or three pharmacies near you (a large chain, an independent, and a warehouse club if one is nearby) or check a live pharmacy pricing tool on the day you plan to fill the prescription, since prices at any given location can shift week to week.

What the New Haven free clinic study does and does not tell us

One Connecticut-specific data point exists in the peer-reviewed literature: a 2024 study examined the cost of medications, including statins, at a student-run free clinic in New Haven between 2021 and 2023 (PubMed). This is a real, Connecticut-located data source, but it describes medication costs within a specific charity-clinic dispensing model serving an uninsured or underinsured population, not typical retail or insurance-based pricing. It should not be read as representative of what a commercially insured or Medicaid patient pays at a CVS or Walgreens in Hartford. If you are a patient or clinician trying to use this study's findings, verify the exact figures and population directly in the paper rather than relying on a secondhand summary, and do not extrapolate a free-clinic acquisition cost to a general retail cash price.

Connecticut Medicaid (HUSKY Health) coverage

Connecticut Medicaid, administered through HUSKY Health, generally covers statins including rosuvastatin, but plan preferred-drug lists commonly place a prior-authorization requirement on rosuvastatin because other statins (such as atorvastatin or simvastatin) may be preferred first-line agents on the formulary. In practice, prior authorization for a non-preferred statin usually requires the prescriber to document one of the following:

• Intolerance or adverse reaction to a preferred statin
• Failure to reach LDL-C goals on a preferred statin
• A specific clinical reason rosuvastatin is preferred (for example, a drug interaction concern with a preferred agent)

The current HUSKY Health preferred drug list, prior-authorization criteria, and typical turnaround time are administrative details that change periodically. This article does not attempt to state a specific turnaround time or approval rate, since we do not have a current, sourced figure for either. Confirm directly with HUSKY Health or your prescriber's office.

For Connecticut residents on Medicare Part D rather than Medicaid, coverage tier and copay depend entirely on the specific Part D plan's formulary for the current plan year. Generic statins are commonly placed on lower tiers, but this is a plan-by-plan fact, not a guaranteed rule.

Commercial insurance in Connecticut

Major carriers offering plans through Access Health CT (the state's ACA marketplace), including Anthem Blue Cross Blue Shield, ConnectiCare, and Aetna, generally include generic statins such as rosuvastatin on their formularies. Brand-name Crestor is more likely to be excluded, placed on a non-preferred brand tier, or subject to step therapy requiring a documented trial of the generic first. Because the active ingredient is identical between brand and generic, there are few clinical scenarios where a patient needs to insist on the brand product specifically; a documented allergy to a specific inactive ingredient (filler, dye, or coating) in the generic tablet is one of the more plausible reasons, and that scenario overlaps with the compounding option described below.

Exact copay amounts, tier placement, and prior-authorization rules vary by employer group and plan year even within the same insurance carrier. The only reliable way to know your specific cost is to check your plan's current formulary or call the number on your insurance card.

Compounded rosuvastatin

Connecticut permits compounding of commercially available drugs, including rosuvastatin, through pharmacies licensed by the state's Department of Consumer Protection and operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounding under 503A requires an individual, patient-specific prescription and is typically used when a patient has a documented need that a manufactured tablet cannot meet, such as:

• Allergy or sensitivity to an inactive ingredient (dye, filler, or coating) in the commercial tablet
• Difficulty swallowing tablets, where a compounded oral suspension may be appropriate
• A non-standard dose that is not available as a manufactured strength

Compounded rosuvastatin is not an FDA-approved finished drug product. The FDA has stated that compounded medications do not go through the same premarket review for safety, efficacy, and quality as approved drugs (FDA: Compounding and the FDA Questions and Answers). Before using a compounded version, confirm the pharmacy holds a current Connecticut compounding license and ask what quality standards it follows. Pricing for compounded rosuvastatin is set by the individual compounding pharmacy and is not something this article can generalize; insurance coverage for compounded products is also inconsistent and should be confirmed in advance.

Discount programs: what exists, and what needs verification each time

Several discount pathways commonly apply to statins nationally, and Connecticut patients can generally access them, but terms, eligibility, and dollar amounts change and should be reconfirmed at the time of use:

• Manufacturer copay cards. AstraZeneca has historically offered copay assistance for brand Crestor for commercially insured patients. These programs typically exclude patients on any government insurance (Medicaid, Medicare, TRICARE). Current eligibility and copay amounts should be verified directly with the manufacturer or at the pharmacy, since terms change.
• Pharmacy discount lists. Several large chains maintain generic drug discount programs that sometimes include statins. Availability and pricing on these lists vary by chain and change over time.
• Coupon aggregator platforms. Sites that aggregate pharmacy cash prices can show a range of prices for a given ZIP code on a given day, but the number shown is a snapshot, not a fixed rate, and cannot be combined with insurance.
• Patient assistance programs. Manufacturer patient assistance programs for brand-name statins sometimes exist for uninsured patients below an income threshold, but eligibility rules and program availability change and should be verified directly with the manufacturer before assuming eligibility.

Telehealth prescribing in Connecticut

Connecticut's telehealth parity law generally requires insurers to cover telehealth visits on comparable terms to in-person visits, and rosuvastatin can be prescribed through a telehealth visit when clinically appropriate, including lipid panel review and cardiovascular risk assessment. The prescriber must be licensed in Connecticut or hold a valid credential to practice telemedicine in the state. This can reduce both travel burden and visit cost for patients in areas farther from a lipid or primary care clinic, though specific visit costs vary by platform and insurance status and are not something this article can quote as a fixed number.

Guideline-based monitoring after starting a statin generally involves a follow-up fasting lipid panel some weeks after initiation, then periodic rechecks; the exact interval should come from your prescriber based on your clinical situation, not a fixed schedule quoted online.

How rosuvastatin compares to other statins

Rosuvastatin is generally considered one of the more potent statins on a per-milligram basis, and is one of two statins (with atorvastatin) recognized in cholesterol management guidelines as a high-intensity option at higher doses. The original placebo-controlled outcomes trial for rosuvastatin in patients with elevated inflammatory markers, and a head-to-head dose-comparison trial against other statins, are both part of the evidence base supporting its guideline positioning. This article deliberately does not restate specific relative-risk percentages or LDL-reduction percentages from those trials here, because the citation identifiers available to us for those studies could not be independently verified against the source material provided, and a wrong number attributed to a real trial is worse than no number. If you need the exact effect sizes for a clinical or patient-facing decision, pull them directly from the trial publication or the current FDA label rather than from a secondary summary.

What is established without needing a specific number: rosuvastatin has fewer CYP3A4-mediated drug interactions than atorvastatin, which can matter for patients on certain macrolide antibiotics, azole antifungals, or specific antiretroviral medications. From a Connecticut cost standpoint, generic rosuvastatin and generic atorvastatin are both low-cost generic statins, so the choice between them is typically driven by tolerability, interaction profile, and how well a patient's LDL-C responds, not by price.

Dosing, safety, and monitoring basics

Rosuvastatin is dosed once daily, with or without food, generally starting between 5 mg and 20 mg depending on baseline LDL-C, cardiovascular risk, and treatment goal, with 40 mg as the maximum approved dose for patients who do not reach target on lower doses. The current FDA label recommends a lower starting dose in patients of Asian descent due to higher observed systemic exposure, and dose limits apply in patients with significant renal impairment. This is general labeling information, not individualized dosing advice; your prescriber determines your specific starting dose and any adjustments.

Common side effects include muscle aches, headache, nausea, and abdominal discomfort. Rare but serious risks include rhabdomyolysis and liver injury, which is why baseline liver function testing before starting therapy, and follow-up testing if symptoms of liver problems develop, is standard practice. Seek urgent medical care for unexplained severe muscle pain with weakness or dark urine, or for signs of liver injury such as jaundice or persistent abdominal pain, rather than waiting for a routine follow-up visit.

Statins as a drug class have a well-established evidence base for reducing cardiovascular events and, in some analyses, all-cause mortality in appropriately selected patients, based on multiple randomized trials and systematic reviews conducted over more than two decades. The specific trial names and effect sizes commonly cited for this class should be checked against the primary literature or a current guideline document rather than assumed from a secondary source, consistent with the caution above.

Verification checklist: stable facts vs. facts you must confirm today

Use this to separate what you can treat as durable background from what requires a fresh check before you act on it.

Stable, unlikely to change quickly (safe to treat as background):

• Rosuvastatin is FDA-approved for hyperlipidemia, cardiovascular risk reduction in specific populations, and slowing atherosclerosis progression.
• Generic rosuvastatin calcium has been available since patent exclusivity ended in 2016, from multiple manufacturers listed in the FDA Orange Book.
• Rosuvastatin is dosed once daily, 5 mg to 40 mg, with a lower recommended starting dose in patients of Asian descent and in severe renal impairment, per the current FDA label.
• Compounding of rosuvastatin under 503A requires an individual patient-specific prescription and a licensed compounding pharmacy; compounded products are not FDA-approved finished drugs.
• Connecticut has a telehealth parity law requiring comparable insurance coverage of telehealth visits.

Date-sensitive facts you must reconfirm before relying on them (verify the same week you act):

• Brand Crestor's manufacturer list price.
• Cash price for a specific rosuvastatin strength at a specific Connecticut pharmacy.
• Whether your specific HUSKY Health or Medicare Part D plan requires prior authorization, and its current turnaround time.
• Your specific commercial plan's copay tier for generic rosuvastatin and for brand Crestor this plan year.
• Whether a manufacturer copay card or patient assistance program is currently active, and its eligibility rules.
• Whether a specific pharmacy discount list currently includes rosuvastatin.

How to verify: call the dispensing pharmacy directly, call the number on your insurance card, or check your plan's current formulary document online. Do not rely on a cached price shown by a discount app without confirming it at the counter, since displayed prices can be out of date.

When to seek urgent care rather than wait

Contact your prescriber promptly, or seek urgent care, if you develop unexplained muscle pain with weakness, dark or cola-colored urine, yellowing of the skin or eyes, severe abdominal pain, or signs of an allergic reaction after starting rosuvastatin. These are not routine side effects to monitor at your next scheduled visit.

Common questions

Is brand Crestor ever medically necessary over generic rosuvastatin? Rarely. Because generic rosuvastatin contains the same active ingredient, the main scenario where brand or a compounded version might be considered is a documented sensitivity to a specific inactive ingredient in the generic tablet, which your prescriber and pharmacist can evaluate.

Does Connecticut Medicaid require prior authorization for rosuvastatin? Generally yes, because HUSKY Health's preferred drug list commonly favors other statins first-line. Confirm the current criteria and turnaround time directly with HUSKY Health, since preferred drug lists are updated periodically.

Can a Connecticut telehealth visit start or manage rosuvastatin therapy? Yes, provided the prescriber is licensed in Connecticut or holds a valid telemedicine credential to practice in the state, and appropriate lipid and safety monitoring is arranged.

References

1. U.S. Food and Drug Administration. Crestor (rosuvastatin calcium) prescribing information. FDA label
2. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA Orange Book
3. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov
4. The Cost of Medications at a Student-Run Free Clinic in New Haven, Connecticut, 2021-2023 (2024). PubMed

This article is intended for general education and does not substitute for individualized medical or insurance advice. Pricing and coverage details noted as date-sensitive above should be confirmed directly with your pharmacy, prescriber, or insurer before you rely on them.